Ibalizumab
Ibalizumab
Ibalizumab (pronounced as i-bal-iz-u-mab) is a monoclonal antibody designed for the treatment of HIV infection. It is also known by its brand name, Trogarzo.
Etymology
The name "Ibalizumab" follows the INN naming convention for monoclonal antibodies, with the suffix "-mab" indicating its classification. The prefix "Iba-" does not have a specific meaning, as it is part of the stem used to identify the drug.
Usage
Ibalizumab is used in combination with other antiretroviral drugs to treat HIV infection in adults who have tried multiple HIV medications in the past. It is administered intravenously and works by blocking the virus from entering T cells, which are a type of white blood cell that the virus typically infects.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- HIV infection: A disease of the human immune system caused by the human immunodeficiency virus (HIV).
- Antiretroviral: A type of drug used to prevent a retrovirus, such as HIV, from replicating.
- T cells: A type of white blood cell that is of key importance to the immune system and is at the core of adaptive immunity, the system that tailors the body's immune response to specific pathogens.
External links
- Medical encyclopedia article on Ibalizumab
- Wikipedia's article - Ibalizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski